MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias

Significance The Src family of nonreceptor tyrosine kinases (SFK) is essential for nervous system function and may contribute to neurodegeneration. Spinocerebellar ataxias (SCAs) are neurodegenerative diseases in which Purkinje neurons fire irregularly and degenerate leading to motor problems. We show that the SFK suppressor Missing-in-metastasis (MTSS1) is an ataxia gene that links multiple SCAs. MTSS1 loss results in increased SFK activity, degenerating Purkinje neurons with low firing rates, and cell death. Surprisingly, mouse models for three different SCAs show elevated SFK activity, with SCA1 and SCA2 models displaying dramatically reduced MTSS1 protein levels. Treatment of each SCA model with an SFK inhibitor corrects Purkinje basal firing and delays ataxia progression in MTSS1 mutants. Our results identify a common link among disparate neurodegenerative diseases. The genetically heterogeneous spinocerebellar ataxias (SCAs) are caused by Purkinje neuron dysfunction and degeneration, but their underlying pathological mechanisms remain elusive. The Src family of nonreceptor tyrosine kinases (SFK) are essential for nervous system homeostasis and are increasingly implicated in degenerative disease. Here we reveal that the SFK suppressor Missing-in-metastasis (MTSS1) is an ataxia locus that links multiple SCAs. MTSS1 loss results in increased SFK activity, reduced Purkinje neuron arborization, and low basal firing rates, followed by cell death. Surprisingly, mouse models for SCA1, SCA2, and SCA5 show elevated SFK activity, with SCA1 and SCA2 displaying dramatically reduced MTSS1 protein levels through reduced gene expression and protein translation, respectively. Treatment of each SCA model with a clinically approved Src inhibitor corrects Purkinje neuron basal firing and delays ataxia progression in MTSS1 mutants. Our results identify a common SCA therapeutic target and demonstrate a key role for MTSS1/SFK in Purkinje neuron survival and ataxia progression.

The genetically heterogeneous spinocerebellar ataxias (SCAs) are caused by Purkinje neuron dysfunction and degeneration, but their underlying pathological mechanisms remain elusive. The Src family of nonreceptor tyrosine kinases (SFK) are essential for nervous system homeostasis and are increasingly implicated in degenerative disease. Here we reveal that the SFK suppressor Missing-in-metastasis (MTSS1) is an ataxia locus that links multiple SCAs. MTSS1 loss results in increased SFK activity, reduced Purkinje neuron arborization, and low basal firing rates, followed by cell death. Surprisingly, mouse models for SCA1, SCA2, and SCA5 show elevated SFK activity, with SCA1 and SCA2 displaying dramatically reduced MTSS1 protein levels through reduced gene expression and protein translation, respectively. Treatment of each SCA model with a clinically approved Src inhibitor corrects Purkinje neuron basal firing and delays ataxia progression in MTSS1 mutants. Our results identify a common SCA therapeutic target and demonstrate a key role for MTSS1/SFK in Purkinje neuron survival and ataxia progression. neurodegeneration | Src kinase | BAR domain proteins | spinocerebellar ataxia | actin cytoskeleton N eurons are nondividing cells that depend on homeostatic regulation of protein, RNA, and metabolite turnover to permit dynamic synaptic connections that allow adaptation to changing environments. Loss of such mechanisms results in one of several hundred neurodegenerative disorders. Over 40 loci form the genetic basis for human spinocerebellar ataxia (SCA), a progressive motor disorder characterized by cerebellar atrophy and pervasive Purkinje neuron degeneration in which patients experience poor coordination and balance, hand-eye coordination, dysarthria, and abnormal saccades.
One common phenotype prominent in multiple SCA animal models is the altered Purkinje neuron firing rates that precede motor impairment and cell death (1)(2)(3), with restoration of the normal firing rates reducing Purkinje neuron death and improving motor function (4,5). Defects in many cell functions, including effectors of transcription (6), translation (7), proteostasis (8,9), calcium flux (10,11), and cytoskeletal/membrane interactions (12,13), lead to SCA. An open question that remains is how the many SCA genes interact to control firing rates and cell survival, with a common target emerging as an ideal treatment for the genetically diverse etiologies.
One such therapeutic target is the class of Src family of nonreceptor tyrosine kinases (SFKs). Several SFKs are expressed in the nervous system and have partially overlapping functions. While single mutants for Src or Yes kinase have no overt neuronal phenotype (14,15), Fyn loss of function leads to increased Src activity and hippocampal learning and memory deficits (16,17). Moreover, Fyn;Src double mutants rarely survive past birth and have severely disorganized cortical and cerebellar layers (15,18). SFKs are posttranslationally regulated through activating and inhibitory phosphorylation marks deposited by inhibitory kinases and are removed by receptor tyrosine phosphatases in a contextdependent manner (19,20). SFK activation occurs rapidly in response to extracellular signals and in response to a variety of cellular stressors ranging from osmotic pressure (21) to tetanic stimulation (22). Additionally, SFKs are inappropriately active in disease states including amyotrophic lateral sclerosis (23), Alzheimer disease (24), and Duchenne muscular dystrophy (25).
Missing-in-metastasis (MTSS1) is one of the defining members of the I-BAR family of negative membrane curvature-sensing proteins first identified as being deleted in metastatic bladder cancer (26). Although MTSS1 biochemically interacts with membranes and regulates the actin cytoskeleton (27), genetic studies reveal that MTSS1 functions in an evolutionarily conserved signaling cassette to antagonize Src kinase activity (28,29). Disruption of the MTSS1/Src regulatory cassette results in endocytosis and polarization abnormalities demonstrated by defects in primary cilia-dependent hedgehog signaling, and hair follicle epithelial migration (28). In tissues requiring MTSS1 function, levels of active MTSS1 are critical, as loss (26) or gain (30) of MTSS1 has been associated with metastasis and invasion. Regardless of the particular phenotype, an evolutionarily conserved property of MTSS1 mutants is that loss of MTSS1 function can be reversed through

Significance
The Src family of nonreceptor tyrosine kinases (SFK) is essential for nervous system function and may contribute to neurodegeneration. Spinocerebellar ataxias (SCAs) are neurodegenerative diseases in which Purkinje neurons fire irregularly and degenerate leading to motor problems. We show that the SFK suppressor Missing-in-metastasis (MTSS1) is an ataxia gene that links multiple SCAs. MTSS1 loss results in increased SFK activity, degenerating Purkinje neurons with low firing rates, and cell death. Surprisingly, mouse models for three different SCAs show elevated SFK activity, with SCA1 and SCA2 models displaying dramatically reduced MTSS1 protein levels. Treatment of each SCA model with an SFK inhibitor corrects Purkinje basal firing and delays ataxia progression in MTSS1 mutants. Our results identify a common link among disparate neurodegenerative diseases.
the removal or inhibition of Src kinases. This property was demonstrated first through double-mutant analysis in the fly ovary and subsequently in mammalian tissue culture using Src family kinase inhibitors (28,29). The availability of Food and Drug Administration (FDA)-approved Src kinase inhibitors has led to the investigation of clinically relevant MTSS1 phenotypes with the hope of using SFK inhibitors to ameliorate them.
Although SFKs have been shown to regulate multiple classes of neurotransmitter receptors (31), they also function to control basic cytoskeletal components. Src regulates local actin polymerization (32) and endocytic receptor internalization (32)(33)(34)(35). The actin cytoskeleton plays a critical role in cell signaling, proliferation, motility, and survival. Local, rather than global, actin dynamics control homeostatic synaptic signaling, and abnormalities in actin regulation underlie a diversity of psychiatric and neuronal diseases including amyotrophic lateral sclerosis (36), schizophrenia, autism spectrum disorders (37), and motor dysfunctions such as SCA (38). Remaining major challenges are understanding how actin cytoskeletal regulation controls synaptic function and developing improved therapeutics for these common and poorly treated diseases.
Here we reveal that the actin regulator and SFK antagonist Mtss1 is an ataxia locus regulated by multiple SCA alleles that subsequently result in SFK hyperactivation. We show that clinically available Src inhibitors correct Purkinje neuron firing rates and delay ataxia progression, demonstrating a druggable role for the evolutionarily conserved MTSS1/SFK network in Purkinje neuron survival and ataxia progression.
To our surprise, homozygous MIM EX15 mutants appear normal for cilia-dependent processes with no observed instances of holoprosencephaly or polydactyly after multiple generations. Additionally, MIM EX15 -mutant males are fertile. Instead, MIM EX15 mutants display a striking and progressive ataxia. To better understand the nature of MIM EX15 ataxia, we characterized MIM EX15 mutants using an open field test to evaluate gross motor control. MIM EX15 mutants had reduced velocity (Fig. 1C) and rearing behavior (Fig. 1D), consistent with overall movement defects. To uncouple possible motor and behavioral abnormalities, we evaluated MIM EX15 mutants with a rotarod assay and observed coordination abnormalities as early as age 4 wk (Fig. 1E). Many spinocerebellar ataxias display progressive neurologic phenotypes. To determine whether MIM EX15 animals showed progressive deterioration, we employed a composite test measuring gait, grip strength, and balance (46). We found MIM EX15 animals performed consistently worse than controls, with severity increasing with age (Fig. 1F). MIM EX15 -heterozygous animals displayed 75% of normal protein levels (SI Appendix, Fig. S1C), giving no overt phenotype.
Reduced Mtss1 levels are associated with a variety of cellular phenotypes including reduced presentation of receptors on the cell membrane (47) and altered Purkinje neuron morphology (41,44). To determine the basis of the motor abnormalities and to distinguish among these possibilities, we performed histological analysis. At age 4 wk, MIM EX15 mice are ataxic, but their cerebella appeared grossly normal with intact granule, Purkinje neuron, and molecular layers. However, MIM EX15 mutants displayed a progressive loss of Purkinje neurons in all cerebellar lobes, which was readily seen by 8 wk of age (SI Appendix, Fig.  S1A). Wild-type cerebella contain approximately eight Purkinje neurons in a 250-μm linear distance, whereas 8-wk-old MIM EX15 mutants retained only 25% and 36-wk-old MIM EX15 mutants had only 5% of the total number of Purkinje neurons found in wildtype mice (Fig. 1G).
While ataxia genes can act in many cell types to regulate Purkinje cell function, MTSS1 is highly expressed in Purkinje cells, suggesting it is required in these cells for normal Purkinje cell function and survival. To confirm that the Purkinje neuron defects seen in MIM EX15 animals are due to a cell-autonomous requirement for Mtss1, we conditionally inactivated Mtss1 using the Purkinje neuron-specific L7-Cre (MIM cko ) and then compared Purkinje neuron morphology and loss to that in the global MIM EX15 mutant. MIM cko Purkinje neurons were mosaic for MTSS1 expression, likely due to inefficient LoxP recombination as the MTSS1 antibody showed high specificity (SI Appendix, Fig. S1B). At age 20 wk MIM cko mice had a significant reduction in Purkinje neurons. In the remaining Purkinje neurons, those lacking MTSS1 protein displayed thickened dendritic branches and reduced arbor volume, while neighboring Purkinje neurons with MTSS1 protein appeared normal (Fig. 1H). We conclude that Mtss1 acts cell autonomously to maintain dendritic structure in Purkinje neurons, with loss of MTSS1 resulting in abnormalities and eventual cell death.

Mtss1 Mutant Neurons Display Limited Autophagic
Markers. An emergent mechanism of cell loss during neurodegeneration is aberrant macroautophagy. Autophagy is essential for Purkinje neuron survival, as loss of autophagy (48,49) results in cell death. Increased levels of early autophagy markers have been described in multiple neurodegenerative diseases including Huntington's disease (50), Alzheimer disease (51), and SCA3 (52). MIM EX15 mutants partially fit this pattern of disease, as we observed some signs of autophagy. As early as age 4 wk, we observed increased complex V/ATP synthase staining indicative of fused mitochondria as well as dramatically reduced staining for the Golgi body marker giantin ( Fig. 2A). We also observed increased transcript abundance for the early autophagy effector VMP1 (53). By 8 wk of age, we could detect increased LC3-II species ( Fig. 2B and SI Appendix, Fig. S2A), and electron microscopy revealed several autophagy-related morphologies, including swollen mitochondria, fragmented Golgi bodies, lamellar bodies, and double-membrane autophagic vacuoles (SI Appendix, Fig. S2C). Interestingly, we were unable to detect increased Sqstrm1 (p62) transcript or protein levels in MIM EX15 , an autophagocytic adapter protein associated with protein aggregation in neurodegenerative disease (SI Appendix, Fig. S2B) (54). MIM EX15 animals displayed increased neuroinflammation shown by increased levels of Aif1 transcript, a readout of microglial infiltration (Fig. 2D). MIM EX15 animals also show increased GFAP + glial infiltration ( Fig. 2 E and F and SI Appendix, Fig. S1A) consistent with reactive astroglyosis. Consistent with the signs of autophagocytic cell death and neuro-inflammation, we failed to see increased DNA breaks in MIM EX15 Purkinje neurons with TUNEL staining (Fig. 2G).

Mtss1 Prevents SFK-Dependent Purkinje Neuron-Firing Defects and
Ataxia. To characterize the cellular changes associated with the ataxia present in 4-wk-old MIM EX15 mice, we examined the dendritic tree of individual biocytin-injected Purkinje neurons (Fig. 3A). Purkinje neuron dendritic arbor collapse has been observed in several SCA models including SCA1 (2) and SCA5 (3), while many other models, including SCA2 (1) and SCA3 (55), have shown a thinned molecular layer that likely reflects reduced Purkinje dendritic volume. Similarly, MIM EX15 mutants showed a 60% reduction in the expansiveness of the dendritic tree (Fig. 3B) and a significant decrease in the number of dendritic spines (Fig. 3C), although no significant difference was detected in spine length (Fig. 3D) or width (Fig. 3E).
In dermal fibroblasts and Drosophila border cells MTSS1 functions locally to prevent ectopic Src kinase activity, and Mtss1mutant phenotypes can be rescued by genetically removing Src kinase (28,29). To determine if Mtss1 acts similarly in Purkinje neurons, we evaluated SFK activity levels in cerebellar lysates from MIM EX15 mutants and found elevated levels of SFK Y416 (Fig. 3F) indicative of increased SFK activity. Previous work has shown strong functional interactions between SFK and metabotropic glutamate receptor type I (mGluR1) neurotransmission at parallel fiber (PF) synapses (56). To investigate whether MTSS1/SFK modulation of mGluR1 signaling forms the basis of the ataxia, we performed electrophysiological analysis of Purkinje neurons in cerebellar slices from MIM EX15 mice. We evaluated Purkinje neuron response to PF stimulation using calcium imaging. We found MIM EX15 -mutant Purkinje neurons responded with an increase of calcium-dependent fluorescence comparable to that in controls, while adding the mGluR1 antagonist CPCCOEt abolished these responses (Fig. 3G). These data support MTSS1 acting downstream of glutamate receptors to control Purkinje cell function.
Purkinje neurons maintain a cell-autonomous tonic firing rate that is essential for their function (57,58). Since MIM EX15 Purkinje neurons responded normally to PF stimulation, suggesting normal synaptic transmission, we assayed the basal firing rate. The Purkinje neuron tonic firing rate is highly sensitive to temperature and may vary slightly with experimental conditions (59). In our assays, wild-type cells had a mean firing rate of 43 ± 2 Hz (n = 2 animals, 62 cells), while 4-wk-old MIM EX15 mutants exhibited a mean firing rate of 12 ± 1 Hz (n = 2 animals, 55 cells) (Fig. 3 H and I). Previous studies of SCA mouse models demonstrated that reduced tonic firing is a basis for ataxia (1,3,5). Since basal firing is reduced at an age when MIM EX15 mice possess a normal number of Purkinje neurons, our results suggest neuron malfunction rather than neuron loss underlies the initial ataxia phenotype.
MTSS1/Src double mutants rescue MTSS1 phenotypes in Drosophila and vertebrate cell culture. To test the hypothesis that reducing SFK activity would ameliorate the MIM EX15 ataxia phenotype, we added the FDA-approved SFK inhibitor dasatinib to cerebellar slice preparations using a concentration approximately twofold over the in vivo IC 50 concentration (200 nM) and measured the basal firing rate (Fig. 3 H and I). Dasatinib significantly increased the MIM EX15 basal firing rate from baseline to 29 ± 1 Hz (n = 2 animals, 62 cells). We also observed that dasatinib slightly reduced the wild-type basal firing rate to 35 ± 1 Hz (n = 2 animals, 79 cells). Time-course experiments showed the increase in basal firing rate occurred over 5 h (SI Appendix, Fig.  S3), consistent with a low-concentration, high-affinity mechanism of action. Direct modulation of ion channel or mGluR1 activity raises basal firing within minutes (4,60), suggesting that dasatinib works through a distinct mechanism. To determine whether SFK inhibition ameliorates ataxia in vivo, we administered dasatinib directly to the cerebellum via minipumps to overcome poor CNS bioavailability (61). Over 4 wk, dasatinib-treated MIM EX15 mice were protected from disease progression while untreated mice showed progressively worsening rotarod performance (n = 2 dasatinib-treated mice and 3 control mice) (Fig. 3J). These results demonstrate that Src family kinases act downstream of MTSS1 and that SFK inhibitors rescue Mtss1-dependent basal firing rate defects to slow disease progression.
Mtss1 Is a Translation Target of ATXN2. The slow basal firing and ataxia preceding cell death seen in the MIM EX15 mutants resembles that seen in other SCA models such as SCA1, SCA2, and SCA5, prompting us to investigate whether MTSS1/SFK dysregulation occurs in other ataxias. SCA2 is caused by an expansion in the polyglutamine (polyQ) tract of the RNA-binding protein ATAXIN-2 (ATXN2) to more than 34 repeats (62). The exact molecular defects that drive SCA2 pathogenesis remain unclear, as mice with loss of ATXN2 function do not recapitulate the SCA2 phenotype (63), while intermediate-expansion alleles are associated with increased risk for ALS (64). Atxn2 has an ancestral role in translation control (7,65), which may be altered with the SCA2 mutation, but the exact targets have yet to be described.
We sought to determine whether the age-dependent reduction in Purkinje neuron basal firing frequency seen in ATXN2 Q127 mice is due to elevated SFK activity. Remarkably, the addition of dasatinib to ATXN2 Q127 cerebellar slices restored the basal firing rate from an average of 14 ± 1 Hz (n = 2 animals, 100 cells) to nearly normal levels of 32 ± 2 Hz (n = 2 animals, 72 cells) (Fig. 4  C and D). As in the MIM EX15 mutants, the firing rate reached maximal effect at 5-6 h of SFK inhibition (SI Appendix, Fig. S3), leading us to conclude that inappropriate SFK activity underlies both the ATXN2-and MTSS1-mediated firing phenotype.
The convergence of Mtss1 and ATXN2 on SFK activity suggested they work in a common or parallel molecular pathway. To distinguish between these possibilities, we further interrogated MTSS1 protein levels in ATXN2 Q127 cerebella. While we found reductions of MTSS1 protein (SI Appendix, Fig. S4A) and RNA in ATXN2 Q127 Purkinje neurons (SI Appendix, Fig. S4B), we failed to see comparable changes in ATXN2 levels in 4-wk-old MIM EX15 mice (Fig. 4E). Because ATXN2 possesses RNA-binding activity, and Mtss1 contains a long 3′ UTR, we hypothesized that ATXN2 controls Mtss1 translation in Purkinje neurons. RNAimmunoprecipitation followed by qPCR in cells expressing tagged versions of either WT (ATXN2 Q22 ) or SCA2 (ATXN2 Q108 ) demonstrated both proteins specifically bound MTSS1 mRNA compared with the GAPDH control (Fig. 4F). Using a luciferase reporter fused to the MTSS1 3′ UTR, we were able to map the ATXN2-interacting domain to a central 500-bp region that was sufficient for both RNA-protein interaction and translation control (SI Appendix, Fig. S4 C and D). Furthermore, polyribosome fractionation experiments revealed that pathogenic ATXN2 Q108 was sufficient to block the translation of reporter mRNA fused to the MTSS1 3′ UTR, shifting the transcript from the polyribosome fractions to a detergent-resistant fraction consistent with stress granules (Fig. 4G). These results suggest the pathogenic ATXN2 acts directly as a dominant-negative RNAbinding protein preventing MTSS1 translation. Notably, we observed MTSS1 abundance is reduced in the cerebellum of human SCA patients, bolstering the evolutionary conservation of the ATXN2/MTSS1 interaction (Fig. 4H).

SFK Inhibition Rescues Purkinje Neuron Firing Across SCA Models.
Two other SCA mouse models, SCA1 (2) and SCA5 (3), have been shown to have slow basal firing rates. Much like SCA2, SCA1 is due to a polyQ expansion in the RNA-binding protein ATAXIN-1 (ATXN1) (71). One observed result of the SCA1 allele is changed ATXN1 association with transcriptional regulatory complexes (72), leading to vastly different Purkinje neuron mRNA profiles (73). However, the exact targets that drive SCA1 pathogenesis are still being determined. Unlike SCA1 and SCA2, SCA5 is a more pure cerebellar ataxia due to lesions in the structural protein β-III spectrin (13). β-III spectrin directly binds to and controls the cell membrane localization of EAAT4 (excitatory amino acid transporter 4), a protein involved in the synaptic clearance of glutamate (12,74).
If SCA1 or SCA5 arises similarly to SCA2 by dysregulation of the MTSS1/SFK cassette, we would expect decreased MTSS1 abundance. Indeed, in the ATXN1 Q82 mouse model of SCA1 (75) we observed a 95% decrease in MTSS1 protein abundance (Fig.   5A) with only a 50% reduction in calbindin, suggesting the loss of MTSS1 is not solely due to the loss of Purkinje neurons.

Discussion
While SCA gene functions appear heterogeneous, our study establishes a genetic framework to understand how several SCA loci regulate SFK activity to ensure neuronal homeostasis and survival. We identify β-III spectrin and MTSS1, proteins that link the cell membrane and actin cytoskeleton, as negative regulators of Src family kinases. We show that MTSS1 is a target of the SCA genes ATXN1 and ATXN2 (Fig. 5I), and that increased SFK activity from lesions in MTSS1, SPTNB2 (SCA5), ATXN1 (SCA1), and ATXN2 (SCA2) reduces Purkinje neuron basal firing, an endophenotype that underlies multiple ataxias, providing support for the clinical use of SFK inhibitors in many SCA patients.
Our results reveal a central role for the MTSS1/SFK regulatory cassette in controlling neuronal homeostasis and survival. MTSS1 regulation of SFKs has been demonstrated in several migratory cell types, including metastatic breast cancer and Drosophila border cells. Here we demonstrate the regulatory cassette functioning in nonmigratory postmitotic cells. MTSS1 integrates the cell membrane and cytoskeletal response to local signals by serving as a docking site for the kinases and phosphatases that control actin polymerization (76), a process essential for dendritic spine assembly, maintenance, and function. In fly border cells, MTSS1-regulated SFK activity polarizes the membrane to spatially detect guidance cues. Similarly, MTSS1 functions in neurons to promote dendritic arborization and spine formation, structures that were shown to be essential for maintaining basal firing frequencies, by electrically isolating increasing areas of Purkinje neuron dendrites (59). Other members of the I-BAR family of membrane/cytoskeletal signaling proteins have been implicated in human neurological disorders such as microcephaly (77), but how they interact with MTSS1 remains to be determined.
Disruption of posttranscriptional gene regulation leading to altered proteostasis has recently emerged as a key contributor to neurodegeneration. In the cerebellum, reducing the abundance of the RNA-binding protein Pumilio leads to SCA1-like neurodegeneration through a specific increase in ATXN1 protein levels (78,79). However, Pumilio binds hundreds of transcripts to control protein levels (80,81), suggesting that changing the protein abundance of a few key effector genes posttranscriptionally leads to disease. Our data demonstrate that MTSS1 is a key effector gene whose activity is tightly regulated to prevent Purkinje neuron malfunction. Posttranscriptional control of MTSS1 is disrupted in many disease states such as cancer, where MTSS1 levels are reduced by locus deletion or miRNA overexpression and are associated with increased metastasis and poorer prognosis (67,82). In Purkinje neurons, the SCA1 ATXN1 Q82 allele reduces MTSS1 transcript levels. ATXN1 is thought to act as a transcriptional regulator by associating with the transcriptional repressor Capicua (CIC) (72), although whether the ATXN1/CIC complex occupies the MTSS1 promoter remains to be shown. By contrast, the SCA2 allele ATXN2 Q108 binds the MTSS1 3′ UTR to prevent ribosome binding and MTSS1 translation, ultimately leading to increased SFK activity. ATXN2 (and the redundant protein ATXN2L) have recently been identified in a large complex of 3′ UTR-binding proteins that regulates networks of genes controlling epithelial differentiation and homeostasis (83). Our results suggest other ataxia disease genes that control proteostasis may also regulate MTSS1 abundance, and the strong role for miRNAs in controlling MTSS1 abundance in cancer suggests they may also function as effectors of as yet undescribed ataxia loci.
The identification of the MTSS1/SFK regulatory cassette in multiple ataxias further reinforces the pathological consequences associated with inappropriate SFK activation in response to a variety of cellular stresses. While the cytoskeletal regulator MTSS1 is an evolutionarily conserved SFK inhibitor, SFK effects on Purkinje neuron basal firing may derive from the fundamental roles SFKs play in cell homeostasis outside cytoskeletal control. For example, SFK control of translation is implicated in Alzheimer disease, as reducing SFK activity proves beneficial for Alzheimer disease progression (24) due to SFK control of pathogenic Aβ translation (84). SFK impairment of autophagy is seen in models of amyotrophic lateral sclerosis and Duchenne muscular dystrophy (23,25). Additionally, reduction of Src kinase expression was identified as a suppressor of SCA1 toxicity in Drosophila ommatidia (85), supporting the need for moderating SFK activity. The pleiotropic effects of inappropriate SFK activity suggest that SFK inhibition may be a critical therapeutic node to slow the progression of multiple neurodegenerative disorders including SCAs. Our work points out the need for future development of neuroactive SFK inhibitor variants, as currently approved Src inhibitors were designed for oncology targets and lack potent CNS activity. Further, while we provide data showing that kinase inhibition suppresses MTSS1 loss, we have previously shown that SFK regulation by regulatory receptor tyrosine phosphatases or the deletion of endocytic adapter proteins can also revert the effects of MTSS1 loss. Given the challenge of developing specific kinase inhibitors, our work opens additional therapeutic classes to alleviate the progression of neurodegenerative diseases.
In summary, the identification of Mtss1 as a recessive ataxia locus extends the physiologic functions requiring the MTSS1/SFK signaling cassette, which include cell polarity, migration, and cancer metastasis. Each of these disparate processes highlights the common role MTSS1 plays in integrating the cell membrane and cytoskeletal response to local signals, as the dendritic spine defects seen in MIM EX15 -mutant Purkinje neurons (Fig. 3 A-E) recall the loss of directional cell extensions in migrating Drosophila border cells (29). They also reinforce the critical need to suppress inappropriate SFK activity and provide a therapeutic opportunity for otherwise devastating and debilitating diseases.

Materials and Methods
Generation of the MIM EX15 Allele. To generate the MIM EX15 conditional allele, exon15 was cloned into the PGK-gb2 targeting vector between the 5′ LoxP site and the 3′ LoxP/FRT flanking neomycin cassette. The targeting vector contained a 5.97-kb 5′ homology arm that included exons 12, 13, and 14 and a 2.34-kb 3′ homology arm that included the 3′ UTR. The targeting vector was electroporated into C57bl6 × SV129 ES cells, and Neo-resistant colonies were screened by PCR. Chimeric mice were generated by injecting ES cells into blastocysts, and chimeras were mated to a FLP deleter strain (86). To generate MIM EX15 -null animals, mice with the MIM EX15 conditional allele were crossed to HPRT-Cre mice (87). Cerebellar-specific MIM deletion used the previously described PCP2-Cre line (88). Mice were maintained on a mixed C57bl6 SV129 background and were examined at the listed ages. All animals studies were approved by the Stanford APLAC Review Board #14126.
Human Samples. Paraffin-embedded brain slices from an SCA2 patient were provided by Arnulf H. Koeppen, Albany Medical College, Albany, NY. Non-SCA2 control paraffin-embedded brain slices were provided by Joshua Sonnen, University of Utah School of Medicine, Salt Lake City. Human tissues were maintained and processed under standard conditions consistent with NIH guidelines and conformed to an approved University of Utah Institutional Review Board protocol. Sections were deparaffinized using standard conditions, blocked/permeabilized with 5% donkey serum and 0.3% Triton X-100 in PBS, and processed for immunostaining. The nuclei were stained with DAPI followed by mounting with Fluoromount-G (catalog no. 0100-01; Southern Biotech). Antibody dilutions for tissue immunostainings were 1:500 for the custom-designed MTSS1 antibody and 1:1,000 for the fluorescent secondary antibody: goat anti-rabbit IgG (H + L) antibody, DyLight-488 (catalog no. 35552; Thermo Fisher Scientific). Images were acquired using a Nikon Eclipse Ti confocal microscope in the University of Utah Cell Imaging Core Laboratory and were analyzed by NIS-Elements AR 4.5 software. Because massive degeneration of cerebellum is seen in SCA2 brain tissue, the lobe cannot be verified.

Electrophysiology.
Preparation of SCA2 and Mtss1 cerebellar slices. Acute parasagittal slices of 285-μm thickness were prepared from the cerebella of 4-to 8-wk-old (MIM EX15 ), or 24-to 29-wk-old (ATXN2 Q127 ) mutants and control littermates following published methods (1). In brief, brains were removed quickly and immersed in an ice-cold artificial cerebrospinal fluid (ACSF) solution or an extracellular solution consisting of 119 mM NaCl, 26 mM NaHCO 3 , 11 mM glucose, 2.5 mM KCl, 2.5 mM CaCl 2 , 1.3 mM MgCl 2 , and 1 mM NaH 2 PO 4 , pH 7.4 when gassed with 5% CO 2 /95% O 2 . Cerebella were dissected and sectioned using a Leica VT-1000 vibratome. Slices were initially incubated at 35°C for 35 min and then at room temperature before recording in the same ACSF. Dasatinib (200 nM) was added during cerebellar sectioning and remained on the slices for recording. SCA2 and Mtss1 recordings. Noninvasive extracellular recordings were obtained from Purkinje neurons in voltage-clamp mode at 34.5 ± 1°C. The temperature was maintained using a dual-channel heater controller (Model TC-344B; Warner Instruments), and slices were constantly perfused with carbogen-bubbled extracellular solution alone or with 200 nM dasatinib. Cells were visualized with an upright Leica microscope using a water-immersion 40× objective. Glass pipettes were pulled with a model P-1000 micropipette puller (Sutter Instruments). Pipettes had a 1-to 3-MΩ resistance when filled with extracellular solution and were used to record action potential-associated capacitative current transients near Purkinje neuron axon hillocks with the pipette potential held at 0 mV. Data were acquired at 20 kHz using a Digidata 1440 MultiClamp 700B amplifier, with pClamp10 (Molecular Devices), filtered at 4 kHz. A total of 50-100 Purkinje neurons were measured from each genotype; each recording was 2 min in duration. The experimenter was blinded to the mouse genotype; two to four mice were used per genotype. Simultaneous mGluR excitatory postsynaptic potentials (EPSPs) and calcium were measured in the presence of the GABA A receptor antagonist picrotoxin (PTX) (100 μM), and AMPA receptor blockers (5 μM NBQX and 10 μM DNQX) using a two-photon microscope and a standard electrophysiology set-up. The patch pipettes had a 4-to 5-MΩ resistance when filled with internal solution (135 mM KMS0 4, NaCl, 10 mM Hepes, 3 mM MgATP, and 0.3 mM Na2GTP) containing 200 μM Oregon Green Bapta1 and 20 μM Alexa-Fluor 594. The stimulating electrode was filled with ACSF containing 20 μM Alexa-Fluor 594 and was placed in the dendritic region to stimulate PF synaptic inputs minimally. Slow mGluR EPSPs in control littermates and mutants were elicited by stimulation of PFs with 100-Hz trains of 10 pulses in the presence of receptor antagonists that block AMPA, NMDA, and GABA A receptors. Corresponding intracellular Ca 2+ signals (ΔF/F) for responses for wild-type and mutant mGluR EPSPs were blocked by the mGluR1 antagonist CPCCOET.
Experiments were analyzed using both the Clampfit and Igor algorithms and were further analyzed using Microsoft Excel. Figures were made in the Igor program. Calcium signals were analyzed using SlideBook (Intelligent Imaging Innovations, Inc.). Results are presented as mean ± SEM. All chemicals were purchased from Sigma Aldrich, Tocris, or Invitrogen.
Biocytin Fills of Purkinje Neurons or Intracellular Labeling of Purkinje Neurons with Biocytin. Biocytin filling of Purkinje neurons was performed using recording pipettes filled with 1% Biocytin (Tocris). Purkinje neurons were filled for 15-30 min; then the pipette was removed slowly to enable the cell membrane to reseal. Slices were fixed in 4% paraformaldehyde overnight and washed three times with PBS. Slices were then incubated with Alexa-Fluor 488 streptavidin (1:500, S11223; Thermo Fisher Scientific) in PBS, 0.5% Triton X-100, and 10% normal goat serum for 90 min. After another three PBS washes, the slices were mounted onto a slide with ProLong Gold (Thermo Fisher). Individual biocytin-filled Purkinje cells were visualized on a Leica SP2 AOBS laser-scanning microscope at a 0.5-um step size. Dendritic arbor volume was measured by calculating the biocytin-filled area in each confocal optical section using ImageJ (NIH), adding the areas in each z-stack, and multiplying by the step size.